EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

The Lancet Haematology

ISSN 2352-3026 · Elsevier BV

Neueste Artikel

  1. Phenotype, treatment, and determinants of prognosis in Erdheim–Chester disease: an international, retrospective, cohort study

    Francesco Pegoraro, Francesco Peyronel, Matthias Papo, Jerome Razanamahery, Francesco Catamerò, Giulia Palazzini, Ilaria Fibbi, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Rivière, Achille Aouba, Fleur Cohen-Aubart, Zahir Amoura, Ahmed Idbaih, Xavier Solanich, Polyzois Makras, Vanderson Rocha, Ofer Shpilberg, Oshrat Hershkovitz-Rokah, David L Pottinger, Laura E M Eurelings, Jan A van Laar, Astrid G S van Halteren, Michael Girschikofsky, Matthew J Koster, Nehaal Ahmed, Dongni Yi, Kristian Bowles, Alessandro Tomelleri, Corrado Campochiaro, Kevin O’Brien, Juvianee Estrada-Veras, Pierre Hirsch, Elena Sieni, Gaurav Goyal, Omar Abdel-Wahab, Jean-François Emile, Matthew Collin, Lorenzo Dagna

    Erschienen: 2026-11DOI: 10.1016/s2352-3026(26)00247-4

  2. Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial

    Jeffrey I Zwicker, Aaron P Kithcart, Justin Kaplan, Poulabi Banerjee, Keshini Vyas, Dan Chalothorn, José G Raya, Siyu Li, Laura E Fredenburgh, Mihaela Mocan, Rosen Razboynikov, Lori G Morton, David E Gutstein, Kathryn M Musgrave, Gregory Piazza, Mihaela Mocan, Rosen Razboynikov, Lucian Calmac, Jeffrey I Zwicker, Gregory Piazza, Gerald Soff, Hannah Lee, Ilana Kopolovic, Alejandro Lazo-Langner, Rashid Kazmi, Ariella Tvito, Amichay Meirovitz

    Erschienen: 2026-11DOI: 10.1016/s2352-3026(26)00249-8

  3. Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial

    Zhongli Hu, Zhiping Fan, Min Dai, Hai He, Hua Jin, Zhiqiang Sun, Fen Huang, Na Xu, Qianwei Liu, Yiqing Li, Ying Dong, Ping Zhu, Can Liu, Yunxin Zeng, Jing Sun, Ruijuan Sun, Li Xuan, Qifa Liu

    Erschienen: 2026-11DOI: 10.1016/s2352-3026(26)00250-4

  4. Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group

    Ali Bazarbachi, Mathilde Fekom, Carmen Martinez, Irma Khvedelidze, Nour Moukalled, Karl S Peggs, Khalid Halahleh, Stefania Bramanti, Sebastian Giebel, Mahmoud Aljurf, Ioanna Sakellari, Malek Benakli, Francesca Bonifazi, Raffaella Cerretti, Raynier Devillier, Alexander Kulagin, Emma Nicholson, Edouard Forcade, Jan Walewski, Alina Tanase, Anna Sureda

    Erschienen: 2026-08DOI: 10.1016/s2352-3026(26)00169-9

  5. Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party

    Ali Bazarbachi, Ranjana Advani, Sairah Ahmed, Carmelo Carlo-Stella, Luca Castagna, Dennis A Eichenauer, Jean El-Cheikh, Mehdi Hamadani, Carmen Martinez, Emma Nicholson, Karl S Peggs, Miguel-Angel Perales, Norbert Schmitz, Lena Specht, Alina Daniela Tanase, Francesco Onida, Annalisa Ruggeri, Cédric Rossi, Mahmoud Aljurf, Marc André, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha, Anna Sureda

    Erschienen: 2026-07DOI: 10.1016/s2352-3026(26)00102-x

  6. Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial

    Nicolò Peccatori, Franco Locatelli, Anneke C J Ammerlaan, Yilin Jiang, Vincent H J van der Velden, Andrej Lissat, Anna Nilsson, Bella Bielorai, Barbara De Moerloose, Susana Rives, Alba Rubio-San-Simon, Uta Dirksen, Gernot Engstler, Benedicte Bruno, Cristina Diaz-de-Heredia, Benoit Brethon, Francisco Bautista Sirvent, Fanny Rialland, Lucie Sramkova, Marlène Pasquet, Karsten Nysom, Nicoletta Bertorello, Peter Bader, Jochen Buechner, Inge M van der Sluis, Berna Beverloo, Barbara Sleight, Arend von Stackelberg, Christian Michel Zwaan, Erica Brivio

    Erschienen: 2026-07DOI: 10.1016/s2352-3026(26)00104-3

  7. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial

    Umberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, Michal Kwiatek, David Belada, Wojciech Jurczak, Marie Maerevoet, David Sibon, Richard Greil, Takahiro Kumode, Javier López-Jimenez, Caressa Meert, Juan-Manuel Sancho Cia, Catherine Thieblemont, Sergio Ortegon Alcaide, Won Seog Kim, Raul Cordoba, Monica Wielgos-Bonvallet, Tony Jiang, Yanli Wang, Stephanie McGoldrick, Evelyn Guo, Franck Morschhauser, F J Sherida H Woei-A-Jin

    Erschienen: 2026-07DOI: 10.1016/s2352-3026(26)00112-2

  8. Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial

    Franck E Nicolini, Gabriel Etienne, Françoise Huguet, Aude Charbonnier, Gabrielle Roth-Guépin, Martine Escoffre-Barbe, Viviane Dubruille, Hyacinthe Johnson-Ansah, Philippe Rousselot, Laurence Legros, Anne Parry, Lydia Roy, Valérie Coiteux, Pascal Lenain, Jean-Christophe Ianotto, Charlotte Doublet, Corentin Orvain, Marion Simonet-Boissard, Marie-Lorraine Chrétien, Amélie Penot, Mathieu Meunier, Shanti Amé, Eric Hermet, Philippe Quittet, Simona Lapusan, Vérane Schwiertz, Jean-Michel Cayuela, Carole Mauté, Delphine Réa, Stéphane Morisset, François-Xavier Mahon, Stéphanie Dulucq

    Erschienen: 2026-05DOI: 10.1016/s2352-3026(26)00043-8

Jahrgänge

2026 · 942025 · 1802024 · 2062023 · 2112022 · 2032021 · 2052020 · 2142019 · 1332018 · 1262017 · 1412016 · 1202015 · 1252014 · 27

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.